



# Effectiveness of Transcranial Direct Current Stimulation on Worry, Anxiety, and Depression in Generalized Anxiety Disorder: A Randomized, Single-Blind Pharmacotherapy and Sham-Controlled Clinical Trial

Fariba Sadeghi Movahed,<sup>1</sup> Jaber Alizadeh Goradel,<sup>2</sup> Asghar Pouresmali,<sup>3</sup> and Mehri Mowlaie<sup>3,\*</sup>

<sup>1</sup>Department of Psychiatry, Ardabil University of Medical Science, Ardabil, Iran

<sup>2</sup>University of Shahid Beheshti, Tehran, Iran

<sup>3</sup>Young Researchers and Elite Club, Ardabil Branch, Islamic Azad University, Ardabil, Iran

\*Corresponding author: Mehri Mowlaie, Young Researchers and Elite Club, Ardabil Branch, Islamic Azad University, Ardabil, Iran. Tel: +98-9142908144, Fax: +98-453235029, E-mail: mehri.molae@yahoo.com

Received 2017 February 19; Revised 2017 July 22; Accepted 2017 September 20.

## Abstract

**Background:** Due to low adherence to treatment and side effects of pharmacotherapy, using new brain stimulation, such as transcranial direct current stimulation (tDCS) in patients with anxiety disorders are available.

**Objectives:** The present research was performed to evaluate the efficacy of tDCS and compare it with pharmacotherapy on reduction of worry, depression, and anxiety in a group of Iranian patients with generalized anxiety disorder (GAD).

**Methods:** This study was a quasi-experimental research. A total of 18 patients (46% females and 54% males) with GAD were randomly assigned either to tDCS, pharmacotherapy or sham conditions. Stimulation was delivered over the contralateral deltoid at 2 mA during 20 minutes in 10 sessions of 4 weeks. Symptoms were assessed by a 7-item GAD scale, HARS, HDRS, and PSWQ in pre-test, post-test and follow up assessment (2 months later). Analysis of variance with repeated measure was used to analyze the data.

**Results:** The results showed that both tDCS and pharmacotherapy were effective in reducing worry symptoms, also the pharmacotherapy group compared with the tDCS group and sham condition was more effective in treating of worry. Anxiety symptoms were reduced by both tDCS and pharmacotherapy and the difference between the 2 methods was not significant. Finally, the effectiveness of tDCS therapy on reducing depressive symptoms was more significant than pharmacotherapy.

**Conclusions:** The tDCS is a promising treatment for generalized anxiety disorder, especially in depressive and worry symptoms.

**Keywords:** Anxiety, Depression, Generalized Anxiety Disorder, tDCS, Worry

## 1. Background

Generalized anxiety disorder, as a chronic disease, is characterized by uncontrollable sense of worry about every aspect of life, physiological symptoms, such as sleep disturbances, muscle tension, irritability, and problem in concentration (1). Prevalence of this disorder has been reported as 4% to 6% (2, 3) in the general population and up to 10% in clinical treatment settings (4). Individuals with GAD have high functional impairment (5, 6) and low quality of life (7).

Both pharmacotherapy and psychotherapy exist for treatment of this disease, yet due to resistance to treatment, low adherence of therapy and adverse side effects, a few of these patients respond to pharmacotherapy (8). Therefore, noninvasive brain stimulation, such as transcranial

direct current stimulation (tDCS) as a vigorous and convenient technique to moderate brain activity, is now available to treat many psychological disorders, such as obsessive-compulsive disorder (9-12), depression (13), and schizophrenia (14). Nevertheless, a few studies on the effectiveness of tDCS on reduction of symptoms of GAD are available. In one research conducted by Shiozawa (15), with positioning of the cathode on right dorsolateral prefrontal cortex RLPFC and the anode on contralateral deltoid, anxiety symptoms were improved during a 15-day treatment course. The present research used anodal stimulation targeting contralateral deltoid and cathodal stimulation on F4 as done in previous research (15). The reason for the use of F4 in cathodal stimulation was its activation during functional neuroimaging (16).

The aim of the present research was to conduct an experimental design using tDCS on reduction of depressive and anxiety symptoms, and worry in patients with GAD. Three major hypotheses were followed from the above aim. Hypothesis 1 stated that tDCS has effective therapeutic influence on reduction of worry. Hypothesis 2 stated that tDCS has effective therapeutic influence on reduction of depressive symptoms. Hypothesis 3 stated that tDCS has effective therapeutic influence on reduction of anxiety symptoms. Finally, the fundamental question of the present research was whether there was a difference in reduction of symptoms between tDCS and pharmacotherapy.

## 2. Objectives

The present research was performed to test the above hypotheses and respond to the question regarding Iranian samples. To do so, a single-blind, randomized clinical trial with sham condition was undertaken.

## 3. Materials and Methods

The present research was quasi experimental, single blind with pre-test, post-test, and follows up assessment (2 months later). A total of 18 patients with generalized anxiety disorder diagnosed by a psychiatrist, participated in this study and were paired according to their age, gender, education, severity, and duration of disease. They were randomly assigned to 2 experimental groups (one with tDCS and the other with pharmacotherapy) and one sham condition. In the tDCS group, subjects received anode electrode on the contralateral deltoid and cathode electrode on the right prefrontal cortex (F4). The mean age of subjects was 28.7 (SD = 9.6). Inclusion and exclusion criteria of the patients were as follows:

### 3.1. Inclusion Criteria

- 1- Diagnosis by a psychiatrist according to diagnostic and statistical manual of mental disorders- fifth edition (DSM-V).
- 2- No previous mental illness.
- 3- No psychological medication.
- 4- Age of 18 to 55 years old.
- 5- No brain injury.
- 6- Five points or higher in the 7-item GAD scale.

### 3.2. Exclusion Criteria

- 1- Drug abuse.
- 2- Current physical or psychological illness, such as schizophrenia, bipolar, and other anxiety disorders.
- 3- Use of medication.

Subjects were randomly assigned to 3 groups of tDCS (6 subjects), pharmacotherapy (6 subjects), and sham condition (6 subjects). This study was carried out according to the the declaration of Helsinki-Ethical principles for Medical research involving human subjects. Written consents were obtained from all participants. It is important to note that sham condition received tDCS treatment after follow up assessment.

### 3.3. Measures

Hamilton anxiety rating scale (HARS) is a 14-item scale that covers 13 symptoms of anxiety developed by Hamilton (17). Each item was rated on a 4-point scale (0 = not present to 4 = severe). The score range was 0 to 56. Those who scored 5 or less were considered as having no anxiety. Other categories were as follows: 6 to 14 = mild anxiety; 15 to 28 = moderate anxiety; 29 to 42 = severe anxiety, and 43 to 56 = very severe anxiety. In Iran, HARS was validated by Kavyani, Mossavi and Mohit (18), and was reported to have high reliability and validity.

Hamilton depression rating scale (HDRS) is a 17-item assessment of depression over the past week developed by Hamilton (19). The cut-off points for different levels of depression were as follows: 0 to 6 = not depressed; 7 to 17 = mildly depressed; 18 to 24 = moderately depressed; and 25 to 64 = severely depressed (20). Carnerio, Fernandes, and Moreno, reported adequate reliability ( $\alpha = 0.83$ ) and validity for this scale (21). In Iran, Mokhber, Azar Pajooh, and Asgharipour (22) reported the reliability of this scale via correlation with BDI as 0.90 and high validity.

Penn state worry questionnaire (PSWQ) is a 16-item scale, which was used to measure individual differences in worry. All items were rated on a 5-point Likert type scale from 1 (not at all typical of me) to 5 (very typical of me). High internal consistency and test-retest reliability were reported (23, 24). Cronbach's alpha for this scale in the present study was 0.90. In Iran, Cronbach's alpha and test-retest reliability was respectively 0.88 and 0.79. Also, the correlation coefficient with trait anxiety and depression was 0.68 and 0.43, which indicated high reliability and validity (25).

### 3.4. Statistical Analysis

All data were analyzed using the SPSS software version 22. Analysis of variance with repeated measures were used to examine the effectiveness of pharmacotherapy and tDCS

on the research variables (worry, anxiety and depression) and also Scheffe follow up test was used to compare the level of effectiveness of these 2 methods.

#### 4. Results


Descriptive statistics of worry, depression, and anxiety scores in 3 stages of treatment was analyzed using mean and standard deviations that are summarized in Figure 1 and Table 1. Inferential results using Analysis of Variance (ANOVA) with repeated measure are shown in Table 2.

In order to analyze the hypotheses of the research, analysis of variance with repeated measures was used. Before analyzing the data, Kolmogorov-Smirnov for examining the normality of data distribution, Leven test for homogeneity of variance, and M-box Matrix variance-covariance were used. In each analysis, the results of Kolmogorov-Smirnov test showed that the P value was more than 0.05. In Leven's test, the hypothesis of equality of variances was met. Finally, the M-box test showed that homogeneity of variance and covariance was fulfilled. The results of worry, depression, and anxiety scores in treatment and sham conditions are shown in Table 2.

As indicated by Table 2, both tDCS and pharmacotherapy compared to the sham condition, were effective in reduction of worry. The level of worry in the treatment groups was significantly reduced in post-treatment and follow up stage compared to the pre-treatment stage. Regarding anxiety, both tDCS and pharmacotherapy compared to the sham condition were effective in reduction of anxiety yet this effectiveness was not statistically significant. In depression, tDCS rather than the sham condition was effective in treatment of depression, yet between-group effects of pharmacotherapy were not significant. Also, in post-treatment and follow up stages compared to pre-treatment stage, the level of depression in tDCS was significantly reduced.

#### 5. Discussion

According to the present research, tDCS was an effective and efficient treatment for patients with generalized anxiety disorders. There were significant improvements in worry (PSWQ), anxiety (HARS), and depression (HDRS) in the experimental groups when compared with the sham condition. Another result of the current research showed that the effectiveness of pharmacotherapy in reducing worry and tDCS in reducing depression was significant. However, in the anxiety variable, there were no significant differences between the 2 treatments. In summary, the results of the present research showed that both tDCS and



**Figure 1.** Comparison Between Effectiveness of Pharmacotherapy, tDCS and Sham Condition Therapy on Treatment of Worry, Depression, and Anxiety in Generalized Anxiety Disorder

pharmacotherapy were effective in treatment of anxiety, depression, and worry compared to the sham condition. Also, the comparison of these 2 treatments showed that the effectiveness of tDCS on depression and pharmacotherapy on worry was more and had equal effect on treatment of anxiety, and there were not significant differences. The current results were consistent with previous researches that showed the effectiveness of tDCS on worry (15), anxiety (25), and depression (26). Brennan, McLoughlin, O'Connell, Bogue, O'Connor, and McHugh (27) showed that tDCS was effective in treatment of depressive symptoms. The studies of Kar and Sarkar (28) showed that the use of brain electrical stimulation was effective in treatment of anxiety. Recent researches with the aim of changing the prefrontal cortex and making an equilibrium between activity of left and right prefrontal cortex, have shown the significant effect of brain direct current stimulation on reduction of symptoms of depression disorder (29).

The novelty of the current research was that tDCS therapy could have effectiveness as much as pharmacotherapy, and in depression cases has even more effectiveness than pharmacotherapy. Conducting more research in the future with more samples could clarify this effectiveness yet what is indisputable is that tDCS is a non-invasive treatment and without side effects compared with pharmacotherapy and its use in clinics on patients, who are resistant and do not have the tendency to use pharmacotherapy, could be an appropriate treatment for anxiety disorders.

**Table 1.** Summary of Descriptive Statistics of Three Measures of Variables in Pre-Post, Post-Test, and Follow Up

Group	Pre-Treatment Phase (M/SD)			Post-Treatment Phase (M/SD)			Follow Up Phase (M/SD)		
	tDCS	Pharmacotherapy	Sham Group	tDCS	Pharmacotherapy	Sham Group	tDCS	Pharmacotherapy	Sham Group
Worry	47 (6)	46 (8.57)	46 (9.01)	38.33 (6.05)	29.16 (6.30)	46.66 (8.31)	38.66 (4.80)	31.66 (4.08)	46.50 (8.87)
Anxiety	44.33 (5.50)	44 (8.69)	42.83 (13.10)	36 (3.57)	35.33 (7.06)	43.33 (12.89)	37 (4.09)	36.50 (5.43)	44.16 (13.31)
Depression	38.66 (9.26)	38.50 (4.59)	41 (8.48)	26.50 (5.04)	35.33 (3.93)	40.50 (8.18)	26.50 (3.97)	34.33 (4.50)	41 (7.37)

**Table 2.** The Result of Analysis of Variance with Repeated Measure of Three Measurements of Study Variables

Variables	Conditions	Source of Changes	SS	df	MS	F	P Value	Eta Square
Worry	Inter-group	factor	743.44	2	371.72	69.79	0.001	0.823
		factor × group	537.44	4	134.36	25.22	0.001	0.771
		error	159.77	30			5.32	
	Between-group	group	1046.44	2	523.38	3.71	0.045	0.331
		error	1505.44	10	150.544			
		factor	309.00	1.44	214.355	49.661	0.001	0.768
Anxiety	Inter-group	factor × group	210.33	2.88	72.59	16.90	0.001	0.693
		error	93.33	21.62	4.31			
		group	254.33.44	2	127.167	0.536	0.596	0.067
	Between-group	error	3557.833	15	237.189			
		factor	345.148	2	172.547	28.429	0.001	0.655
		factor × group	304.741	4	76.185	12.550	0.001	0.626
Depression	Inter-group	error	182.11	30	6.070			
		group	952.259	2	476.130	4.196	0.036	0.359
	Between-group	error	1701.889	15	113.459			

### 5.1. Conclusion

In conclusion, the results of the present research showed that tDCS by using anode electrode on contralateral deltoid and cathode electrode on F4, to decrease worry, anxiety and depression symptoms, in GAD patient is a safe, convenient, and an inexpensive method. Also, a few studies have been done to investigate the impact of brain stimulation on GAD patients; this study might be practical for therapists to combine their therapies with non-invasive brain stimulation in order to increase beneficial effects of tDCS.

### Acknowledgments

This study was sponsored by the Medical University of Ardabil.

### Footnotes

**Authors' Contribution:** Mehri Mowlaie developed the original idea, wrote the manuscript, and collected the data. Asghar Pouresmali, Jaber Alizadeh Goradel and

Fariba Sadeghi Movahed revised the manuscript. All of the authors provided comments and approved the final manuscript.

**Declaration of Interest:** None declared.

**Funding/Support:** Ardabil University of Medical Sciences.

### References

- American Psychiatric Association. *Diagnostic and statistical manual of mental disorders (DSM-5®)*. American Psychiatric Pub; 2013.
- Beesdo K, Pine DS, Lieb R, Wittchen HU. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. *Arch Gen Psychiatry*. 2010;**67**(1):47-57. doi: [10.1001/archgenpsychiatry.2009.177](https://doi.org/10.1001/archgenpsychiatry.2009.177). [PubMed: 20048222].
- Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;**62**(6):617-27. doi: [10.1001/archpsyc.62.6.617](https://doi.org/10.1001/archpsyc.62.6.617). [PubMed: 15939839].
- Brown TA, Barlow DH. Classification of anxiety and mood disorders. In: Barlow DH, editor. *Anxiety and Its Disorders*. **292-329**. 2 ed. New York: Guilford Press; 2002.
- Beesdo K, Hoyer J, Jacobi F, Low NC, Hofler M, Wittchen HU. Association between generalized anxiety levels and pain in a com-

- munity sample: evidence for diagnostic specificity. *J Anxiety Disord.* 2009;**23**(5):684-93. doi: [10.1016/j.janxdis.2009.02.007](https://doi.org/10.1016/j.janxdis.2009.02.007). [PubMed: [19278819](https://pubmed.ncbi.nlm.nih.gov/19278819/)].
6. Berezina BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. *Clin Ther.* 2009;**31**(6):1279-308. doi: [10.1016/j.clinthera.2009.06.004](https://doi.org/10.1016/j.clinthera.2009.06.004). [PubMed: [19695395](https://pubmed.ncbi.nlm.nih.gov/19695395/)].
  7. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. *Am J Psychiatry.* 2000;**157**(5):669-82. doi: [10.1176/appi.ajp.157.5.669](https://doi.org/10.1176/appi.ajp.157.5.669). [PubMed: [10784456](https://pubmed.ncbi.nlm.nih.gov/10784456/)].
  8. Craske MG, Edlund MJ, Sullivan G, Roy-Byrne P, Sherbourne C, Bystritsky A, et al. Perceived unmet need for mental health treatment and barriers to care among patients with panic disorder. *Psychiatr Serv.* 2005;**56**(8):988-94. doi: [10.1176/appi.ps.56.8.988](https://doi.org/10.1176/appi.ps.56.8.988). [PubMed: [16088017](https://pubmed.ncbi.nlm.nih.gov/16088017/)].
  9. Del Casale A, Kotzalidis GD, Rapinesi C, Serata D, Ambrosi E, Simonetti A, et al. Functional neuroimaging in obsessive-compulsive disorder. *Neuropsychobiology.* 2011;**64**(2):61-85. doi: [10.1159/000325223](https://doi.org/10.1159/000325223). [PubMed: [21701225](https://pubmed.ncbi.nlm.nih.gov/21701225/)].
  10. Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. *Trends Cogn Sci.* 2012;**16**(1):43-51. doi: [10.1016/j.tics.2011.11.003](https://doi.org/10.1016/j.tics.2011.11.003). [PubMed: [22138231](https://pubmed.ncbi.nlm.nih.gov/22138231/)].
  11. Volpato C, Piccione F, Cavinato M, Duzzi D, Schiff S, Foscolo L, et al. Modulation of affective symptoms and resting state activity by brain stimulation in a treatment-resistant case of obsessive-compulsive disorder. *Neurocase.* 2013;**19**(4):360-70. doi: [10.1080/13554794.2012.667131](https://doi.org/10.1080/13554794.2012.667131). [PubMed: [22554168](https://pubmed.ncbi.nlm.nih.gov/22554168/)].
  12. Alizadeh Goradel J, Pouresmali A, Mowlaie M, Sadeghi Movahed F. The Effects of Transcranial Direct Current Stimulation on Obsession-compulsion, Anxiety, and Depression of a Patient Suffering from Obsessive-compulsive Disorder. *Practice Clin Psychol.* 2016;**4**(2):75-80. doi: [10.15412/j.jpccp.06040201](https://doi.org/10.15412/j.jpccp.06040201).
  13. Shah DB, Pesiridou A, Baltuch GH, Malone DA, O'Reardon JP. Functional neurosurgery in the treatment of severe obsessive compulsive disorder and major depression: overview of disease circuits and therapeutic targeting for the clinician. *Psychiatry (Edgmont).* 2008;**5**(9):24-33. [PubMed: [19727257](https://pubmed.ncbi.nlm.nih.gov/19727257/)].
  14. Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, et al. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. *Am J Psychiatry.* 2012;**169**(7):719-24. doi: [10.1176/appi.ajp.2012.11071091](https://doi.org/10.1176/appi.ajp.2012.11071091). [PubMed: [22581236](https://pubmed.ncbi.nlm.nih.gov/22581236/)].
  15. Shiozawa P, Leiva AP, Castro CD, da Silva ME, Cordeiro Q, Fregni F, et al. Transcranial direct current stimulation for generalized anxiety disorder: a case study. *Biol Psychiatry.* 2014;**75**(11):e17-8. doi: [10.1016/j.biopsych.2013.07.014](https://doi.org/10.1016/j.biopsych.2013.07.014). [PubMed: [23958182](https://pubmed.ncbi.nlm.nih.gov/23958182/)].
  16. Bystritsky A, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burack M, et al. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. *J Clin Psychiatry.* 2008;**69**(7):1092-8. doi: [10.4088/JCP.v69n0708](https://doi.org/10.4088/JCP.v69n0708). [PubMed: [18572984](https://pubmed.ncbi.nlm.nih.gov/18572984/)].
  17. Hamilton M. The assessment of anxiety states by rating. *Br J Med Psychol.* 1959;**32**(1):50-5. doi: [10.1111/j.2044-8341.1959.tb00467.x](https://doi.org/10.1111/j.2044-8341.1959.tb00467.x). [PubMed: [13638508](https://pubmed.ncbi.nlm.nih.gov/13638508/)].
  18. Kavyani H, Mossavi AS, Mohit A. *Psychological Scales and Interviews*. Tehran: Sana Publications; 2001. Persian.
  19. Hamilton M. A rating scale for depression. *J Neurol Psychiatry.* 1960;**23**(1):56-62. doi: [10.1136/jnnp.23.1.56](https://doi.org/10.1136/jnnp.23.1.56).
  20. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S. Hamilton Depression Rating Scale. Extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia. *Arch Gen Psychiatry.* 1981;**38**(1):98-103. doi: [10.1001/archpsyc.1981.01780260100011](https://doi.org/10.1001/archpsyc.1981.01780260100011). [PubMed: [7458574](https://pubmed.ncbi.nlm.nih.gov/7458574/)].
  21. Carneiro AM, Fernandes F, Moreno RA. Hamilton depression rating scale and montgomery-asberg depression rating scale in depressed and bipolar I patients: psychometric properties in a Brazilian sample. *Health Qual Life Outcomes.* 2015;**13**:42. doi: [10.1186/s12955-015-0235-3](https://doi.org/10.1186/s12955-015-0235-3). [PubMed: [25889742](https://pubmed.ncbi.nlm.nih.gov/25889742/)].
  22. Mokhber N, Azar Pajoo MR, Asgharipour N. [Effect of citalopram on depression and cognitive functions of stroke patients]. *J Sabzevar Univ Med Sci.* Persian.
  23. Fresco DM, Heimberg RG, Mennin DS, Turk CL. Confirmatory factor analysis of the Penn State Worry Questionnaire. *Behav Res Ther.* 2002;**40**(3):313-23. doi: [10.1016/S0005-7967\(00\)00113-3](https://doi.org/10.1016/S0005-7967(00)00113-3). [PubMed: [11863241](https://pubmed.ncbi.nlm.nih.gov/11863241/)].
  24. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. *Behav Res Ther.* 1990;**28**(6):487-95. doi: [10.1016/0005-7967\(90\)90135-6](https://doi.org/10.1016/0005-7967(90)90135-6). [PubMed: [2076086](https://pubmed.ncbi.nlm.nih.gov/2076086/)].
  25. Dehshiri GHR, Golzari M, Borjali A, Sohrabi F. [Psychometrics particularity of farsi version of pennsylvania state worry questionnaire for college students]. *J Clin Psychol.* 2010;**1**(4):67-75. Persian.
  26. Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandel P, et al. Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopram. *Clin Neurophysiol.* 2015;**126**(6):1185-9. doi: [10.1016/j.clinph.2014.09.026](https://doi.org/10.1016/j.clinph.2014.09.026). [PubMed: [25454337](https://pubmed.ncbi.nlm.nih.gov/25454337/)].
  27. Brennan S, McLoughlin DM, O'Connell R, Bogue J, O'Connor S, McHugh C, et al. Anodal transcranial direct current stimulation of the left dorsolateral prefrontal cortex enhances emotion recognition in depressed patients and controls. *J Clin Exp Neuropsychol.* 2017;**39**(4):384-95. doi: [10.1080/13803395.2016.1230595](https://doi.org/10.1080/13803395.2016.1230595). [PubMed: [27662113](https://pubmed.ncbi.nlm.nih.gov/27662113/)].
  28. Kar SK, Sarkar S. Neuro-stimulation Techniques for the Management of Anxiety Disorders: An Update. *Clin Psychopharmacol Neurosci.* 2016;**14**(4):330-7. doi: [10.9758/cpn.2016.14.4.330](https://doi.org/10.9758/cpn.2016.14.4.330). [PubMed: [27776384](https://pubmed.ncbi.nlm.nih.gov/27776384/)].
  29. Arul-Anandam AP, Loo C. Transcranial direct current stimulation: a new tool for the treatment of depression? *J Affect Disord.* 2009;**117**(3):137-45. doi: [10.1016/j.jad.2009.01.016](https://doi.org/10.1016/j.jad.2009.01.016). [PubMed: [19201483](https://pubmed.ncbi.nlm.nih.gov/19201483/)].